Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

EMT and MET: necessary or permissive for metastasis?

Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H.

Mol Oncol. 2017 Jul;11(7):755-769. doi: 10.1002/1878-0261.12083. Epub 2017 Jun 12. Review.

2.

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells.

Ware KE, Gilja S, Xu S, Shetler S, Jolly MK, Wang X, Bartholf Dewitt S, Hish AJ, Jordan S, Eward W, Levine H, Armstrong AJ, Somarelli JA.

J Vis Exp. 2017 Apr 7;(122). doi: 10.3791/55520.

3.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC.

Cancer Res. 2017 Jul 1;77(13):3551-3563. doi: 10.1158/0008-5472.CAN-17-0109. Epub 2017 Apr 20.

4.

PhyloOncology: Understanding cancer through phylogenetic analysis.

Somarelli JA, Ware KE, Kostadinov R, Robinson JM, Amri H, Abu-Asab M, Fourie N, Diogo R, Swofford D, Townsend JP.

Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):101-108. doi: 10.1016/j.bbcan.2016.10.006. Epub 2016 Oct 31. Review.

PMID:
27810337
5.

Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.

Gupta S, Li J, Kemeny G, Bitting RL, Beaver J, Somarelli JA, Ware KE, Gregory S, Armstrong AJ.

Clin Cancer Res. 2017 Mar 1;23(5):1346-1357. doi: 10.1158/1078-0432.CCR-16-1211. Epub 2016 Sep 6.

6.

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.

Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Patierno SR, Freedman J, Foo WC, Garcia-Blanco MA, Armstrong AJ.

Oncotarget. 2016 Aug 2;7(31):50507-50521. doi: 10.18632/oncotarget.10476.

7.

Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.

Somarelli JA, Shetler S, Jolly MK, Wang X, Bartholf Dewitt S, Hish AJ, Gilja S, Eward WC, Ware KE, Levine H, Armstrong AJ, Garcia-Blanco MA.

Mol Cell Biol. 2016 Sep 12;36(19):2503-13. doi: 10.1128/MCB.00373-16. Print 2016 Oct 1.

8.

Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways.

Somarelli JA, Schaeffer D, Marengo MS, Bepler T, Rouse D, Ware KE, Hish AJ, Zhao Y, Buckley AF, Epstein JI, Armstrong AJ, Virshup DM, Garcia-Blanco MA.

Oncogene. 2016 Aug 18;35(33):4302-11. doi: 10.1038/onc.2015.497. Epub 2016 Jan 11.

9.

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Ware KE, Garcia-Blanco MA, Armstrong AJ, Dehm SM.

Endocr Relat Cancer. 2014 Aug;21(4):T87-T103. doi: 10.1530/ERC-13-0470. Epub 2014 May 23. Review.

10.

FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.

Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, Bunn PA Jr, Camidge DR, Tan AC, Hirsch FR, Heasley LE.

Clin Cancer Res. 2014 Jun 15;20(12):3299-309. doi: 10.1158/1078-0432.CCR-13-3060. Epub 2014 Apr 25.

11.

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.

Ware KE, Hinz TK, Kleczko E, Singleton KR, Marek LA, Helfrich BA, Cummings CT, Graham DK, Astling D, Tan AC, Heasley LE.

Oncogenesis. 2013 Mar 25;2:e39. doi: 10.1038/oncsis.2013.4.

12.

Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Marshall ME, Hinz TK, Kono SA, Singleton KR, Bichon B, Ware KE, Marek L, Frederick BA, Raben D, Heasley LE.

Clin Cancer Res. 2011 Aug 1;17(15):5016-25. doi: 10.1158/1078-0432.CCR-11-0050. Epub 2011 Jun 14.

13.

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.

Ware KE, Marshall ME, Heasley LR, Marek L, Hinz TK, Hercule P, Helfrich BA, Doebele RC, Heasley LE.

PLoS One. 2010 Nov 29;5(11):e14117. doi: 10.1371/journal.pone.0014117.

14.

The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer.

Kono SA, Marshall ME, Ware KE, Heasley LE.

Drug Resist Updat. 2009 Aug-Oct;12(4-5):95-102. doi: 10.1016/j.drup.2009.05.001. Epub 2009 Jun 4. Review.

15.

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells.

Marek L, Ware KE, Fritzsche A, Hercule P, Helton WR, Smith JE, McDermott LA, Coldren CD, Nemenoff RA, Merrick DT, Helfrich BA, Bunn PA Jr, Heasley LE.

Mol Pharmacol. 2009 Jan;75(1):196-207. doi: 10.1124/mol.108.049544. Epub 2008 Oct 10.

16.

The nursing attendant's role in a rehabilitation setting: conceptions and attitudinal correlates.

Fuhrer MJ, Ware KE, Scott RW.

Nurs Res. 1968 Jul-Aug;17(4):343-8. No abstract available.

PMID:
5186329
17.

Body-image boundaries and adjustment to poliomyelitis.

WARE KE, FISHER S, CLEVELAND S.

J Abnorm Psychol. 1957 Jul;55(1):88-93. No abstract available.

PMID:
13462665

Supplemental Content

Support Center